Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

Market Cap	15.74B
Revenue (ttm)	624.52M
Net Income (ttm)	-947.49M
Shares Out	399.40M
EPS (ttm)	-2.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,531,797
Average Volume	7,990,158
Open	40.05
Previous Close	40.01
Day's Range	39.22 - 40.86
52-Week Range	15.36 - 63.59
Beta	1.08
RSI	42.76
Earnings Date	Mar 25, 2026

About SHA:688062

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; and JUNMAIKANG, an autoimmune Adalimumab injection. Its oncology product pipeline includes 9MW2821, a Nectin-4 t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 1,416
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688062

Financial Performance

In 2024, SHA:688062's revenue was 199.78 million, an increase of 56.28% compared to the previous year's 127.84 million. Losses were -1.04 billion, -0.90% less than in 2023.